Cheesecake Factory's Price Target Raised to $73 by Stephens

RBC Capital analyst Ben Hendrix maintained a Buy rating for Humana with a $283 price target. The analyst consensus rating for Humana is Moderate Buy with an average price target of $293.25, a 32.15% upside from current levels. Humana has a one-year high of $406.46 and a one-year low of $212.45, with an average volume of 1.74M.

On July 2, 2025, the healthcare sector witnessed a significant shift in analyst ratings and price targets for Humana (HUM, Financial). The latest updates underscore a cautious investment stance on the company as it navigates its future performance within the healthcare sector.

Truist Securities, through its analyst David Macdonald, announced a revision to Humana's price target. The price target was lowered from $280.00 USD to $260.00 USD, reflecting a decrease of 7.14%. Despite this adjustment, Truist Securities maintained its current "Hold" rating for the company's stock [1].

The average target price for Humana Inc (HUM, Financial) based on 22 analysts is $292.78, with a high estimate of $402.23 and a low estimate of $224.00. This average target implies an upside of 30.45% from the current price of $224.44 [1]. The consensus recommendation from 27 brokerage firms is "Hold," indicating a moderate buy status [1].

GuruFocus estimates the GF Value for Humana Inc (HUM, Financial) in one year to be $629.61, suggesting an upside of 180.52% from the current price of $224.4443 [1]. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at.

In the preceding three months, 8 analysts have released ratings for Humana, with a wide array of perspectives from bullish to bearish. The average target is $280.75, accompanied by a high estimate of $310.00 and a low estimate of $260.00. This current average has decreased by 7.0% from the previous average price target of $301.88 [2].

RBC Capital analyst Ben Hendrix maintained a Buy rating for Humana with a $283 price target. The analyst consensus rating for Humana is Moderate Buy with an average price target of $293.25, a 32.15% upside from current levels [3]. Humana has a one-year high of $406.46 and a one-year low of $212.45, with an average volume of 1.74M [3].

Analysts have recently evaluated Humana and provided 12-month price targets. The average target is $280.75, accompanied by a high estimate of $310.00 and a low estimate of $260.00. This current average has decreased by 7.0% from the previous average price target of $301.88 [2].

Humana is one of the largest private health insurers in the US, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program. The company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management [2].

References:
[1] https://www.gurufocus.com/news/2981690/humana-hum-truist-securities-lowers-price-target-but-maintains-hold-rating-hum-stock-news
[2] https://www.nasdaq.com/articles/expert-outlook-humana-through-eyes-8-analysts
[3] https://www.marketbeat.com/instant-alerts/humana-nysehum-lowered-to-hold-rating-by-wall-street-zen-2025-07-12/